Your fact-checks will appear here
The safety and effectiveness of the shingles vaccine, particularly Shingrix, in clinical trials and real-world studies.
The best available post‑licensure evidence finds a very small absolute increase in Guillain–Barré syndrome (GBS) cases in the 42 days after the recombinant zoster vaccine (RZV, Shingrix)—about 3 exces...
The currently recommended shingles vaccine, Shingrix (recombinant zoster vaccine, RZV), has a strong safety and effectiveness record in clinical trials and large real‑world studies, with common short‑...
The pivotal phase 3 ZOE-50 and ZOE-70 trials that supported SHINGRIX licensing were randomized, observer‑blind, placebo‑controlled studies — participants were assigned to receive two doses of the reco...
Shingrix (recombinant zoster vaccine, RZV) has a substantial published evidence base: pivotal phase III trials (ZOE‑50/70 and ZOE‑HSCT), regulatory reviews (FDA, EMA), company pooled datasets and post...
Shingrix is now the preferred shingles vaccine because clinical trials and public-health guidance show substantially higher efficacy than the older live vaccine Zostavax, particularly in older adults,...
Shingrix (recombinant zoster vaccine, RZV) is highly effective at preventing shingles and, based on clinical trials and years of post‑licensure surveillance, has a safety profile marked by frequent sh...